OnKure Therapeutics, Inc. (OKUR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US68277Q1058
OnKure Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -62.95 m USD |
| EBIT | -59.52 m USD |
| Net income | -59.52 m USD |
| Diluted EPS – continuing operations | -4.40 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
More stocks
- Batulicin Nusantara Maritim Tbk PT (BESS.JK)
- Deokyang Energen Corporation (0001A0.KQ)
- HansBiomed Corporation (042520.KQ)
- Hanpin Electron Co Ltd (2488.TW)
- Tonlin Department Store Co Ltd (2910.TW)
- AOPEN Inc (3046.TW)
- Aurona Industries (8074.TWO)
- Vitrafy Life Sciences Ltd (VFY.AX)
- Apyx Medical Corp (APYX)
- Silitech Technology Corp (3311.TW)
- Emro Inc. (058970.KQ)
- Arbor Technology (3594.TWO)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.